"A class of medications long used to curb HIV infection shows promise as a therapy for age-related macular degeneration (AMD), suggest findings from an NIH-funded study. These mainstay HIV drugs, called nucleoside reverse transcriptase inhibitors "...
Advise patients that if serious or unusual ocular or systemic reactions or signs of hypersensitivity occur, they should discontinue the use of the product and consult their physician.
Temporary Blurred Vision
Vision may be temporarily blurred following dosing with SIMBRINZA™. Care should be exercised in operating machinery or driving a motor vehicle.
Effect on Ability to Drive and Use Machinery
As with other drugs in this class, SIMBRINZA™ may cause fatigue and/or drowsiness in some patients. Caution patients who engage in hazardous activities of the potential for a decrease in mental alertness.
Avoiding Contamination of the Product
Instruct patients that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions [see WARNINGS AND PRECAUTIONS]. Always replace the cap after using. If solution changes color or becomes cloudy, do not use. Do not use the product after the expiration date marked on the bottle.
Intercurrent Ocular Conditions
Advise patients that if they have ocular surgery or develop an intercurrent ocular condition (e.g., trauma or infection), they should immediately seek their physician's advice concerning the continued use of the present multidose container.
Concomitant Topical Ocular Therapy
If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.
Contact Lens Wear
The preservative in SIMBRINZA™, benzalkonium chloride, may be absorbed by soft contact lenses. Contact lenses should be removed during instillation of SIMBRINZA™, but may be reinserted 15 minutes after instillation.
Last reviewed on RxList: 5/3/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Simbrinza Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.